Navigation Links
OncoSec Medical to Present at ROTH 23rd Annual Growth Stock Conference
Date:3/15/2011

SAN DIEGO, March 15, 2011 /PRNewswire/ -- OncoSec Medical, Inc. (OTC Bulletin Board: ONCSD) announced today that Mr. Punit Dhillon, President and CEO, will present a company overview on Wednesday, March 16 at 2:00 pm PT at the ROTH 23rd Annual Growth Stock Conference being held at the Ritz-Carlton, Laguna Niguel, CA.

(Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

Conference details: http://www.roth.com/main/Page.aspx?PageID=7236

About OncoSec Medical Inc.

OncoSec (OTC BB: ONCS.D), based in San Diego, California, designs, develops and commercializes innovative and proprietary medical approaches to treat solid tumor cancers with unmet medical needs or where currently approved therapies are inadequate based on their efficacy level or side effect profile. The company's therapies are based on the use of electroporation delivery in combination with an approved chemotherapeutic drug or a cytokine agent to treat solid tumors. More information is available at www.oncosec.com.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE OncoSec Medical Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
2. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
3. LaVoie Group Wins Gold Mercury Award For Medical Device Company, Alphatec Spine
4. Reportlinker Adds Medical Devices Market in Europe 2008-2012
5. R. Lindholm Named to Crux Biomedical Board
6. Varian Medical Systems Schedules Second Quarter FY2011 News Release and Conference Call
7. Dehaier Medical Systems Signs New Distribution Agreement to Distribute eVent Medical Ventilators
8. Mindray Medical to Present at the 14th Annual Credit Suisse Asian Investment Conference on March 21-25
9. Sonitus Medical Receives European CE Mark for SoundBite™ Hearing System
10. BridgePoint Medical Closes $9.1 Million Series C Financing
11. International Prostate Cancer Treatment Expert Dr. David B. Samadi Supports Kenyan Minister of Medical Services, Peter Anyang Nyongos Decision to Travel to the U.S. for Prostate Cancer Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... YORK , March 23, 2017 ... sample preparation market is expected to reach USD 7.2 billion ... of 7.1%. Sample preparation is a procedure in which a ... crucial step in most analytical procedures since the methods are ... preparation is one of the most shared procedures in the ...
(Date:3/23/2017)... Denmark , March 23, 2017 Ascendis ... its innovative TransCon technology to address significant unmet medical ... will host a conference call and webcast on Monday, ... the Endocrine Society in Orlando, Florida ... disease pipeline candidates (TransCon Growth Hormone, TransCon PTH and ...
(Date:3/23/2017)... , March 23, 2017  Cornerstone Pharmaceuticals, ... a major milestone today.  Following successful End-of-Phase ... U.S. Food and Drug Administration (FDA), the ... and regulatory path forward to conduct pivotal ... patients with acute myeloid leukemia (AML) and ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... “My Journey Through Heaven”: the true-life account of ... profound faith of God’s promise of Heaven for His people. “My Journey Through Heaven” ... with his wife, three children and six grandchildren living and doing for God as ...
(Date:3/23/2017)... ... March 23, 2017 , ... “A ... God. “A Respectful Response To Atheist Manifesto” is the creation of published author ... wife, Nancy, for sixty years. He holds graduate degrees from Kent State University ...
(Date:3/23/2017)... ... March 23, 2017 , ... “More Corruption”: a simple and strong explanation of the ... of the rulers of Heaven was asked by God to write a book about Him. ... me just because I kept my commitment to the Lord God. They have not walked ...
(Date:3/22/2017)... ... ... Death anxiety is unconscious and needs understanding and non-judgmental support in a loving ... book titled “ As Good as Goodbyes Get ” (published by Balboa Press AU), ... experiencing at the bedside of patients who were dying. The book centers about questions ...
(Date:3/22/2017)... ... March 23, 2017 , ... ... solutions for drugs, biologics and consumer health products, today announced that it had ... currently taking place at the Suntec Singapore International Exhibition & Convention Centre, Singapore. ...
Breaking Medicine News(10 mins):